This is an ongoing investigation which has already led to a pending class action lawsuit against drug manufacturer Amgen, Inc.
The class action complaint alleges Amgen acted unlawfully in the off-label and deceptive marketing of its drug products known as erythropoiesis-stimulating agents (ESA) drugs, under brand names Epogen and Aranesp. According to the class action complaint Epogen and Aranesp are approved for use with kidney and cancer patients to boost hemoglobin levels and prevent patients from needing a blood transfusion . The lawsuit was filed on behalf of patients who have paid for these drugs where Amgen allegedly marketed the products outside of the bounds of their FDA approvals.
According to the complaint as a result of these practices consumers paid for ESAs when they would not have otherwise done so. If you or anyone you know has been taking Epogen or Aranesp please click here to see if you qualify to join the class.
Do not change medications without first consulting your doctor.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.